BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 1.3% - Should You Sell?

Key Points

• Shares slipped 1.3% — BBOT traded as low as $8.80 and last at $8.91 mid-day on modestly above-average volume, with a market cap of about $713M and a negative trailing PE of -5.86.
• Analyst sentiment leans positive — three Buy ratings versus one Sell give a consensus "Moderate Buy" and a consensus price target of $26.00, signaling significant implied upside from current levels.
• Institutions are adding exposure — institutional ownership is 54.89% and several funds materially increased stakes in the quarter (notably Armistice Capital boosted its position to 1,000,000 shares).

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Get Free Report) shares dropped 1.3% during mid-day trading on Thursday . The company traded as low as $8.80 and last traded at $8.91. Approximately 164,855 shares traded hands during trading, an increase of 2% from the average daily volume of 161,295 shares. The stock had previously closed at $9.03.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Weiss Ratings initiated coverage on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They issued a "sell (d+)" rating on the stock. HC Wainwright lifted their target price on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a "buy" rating in a research report on Friday, March 6th. Raymond James Financial raised shares of BridgeBio Oncology Therapeutics to a "moderate buy" rating in a research note on Friday, January 9th. Finally, Stifel Nicolaus assumed coverage on shares of BridgeBio Oncology Therapeutics in a report on Tuesday, February 10th. They issued a "buy" rating and a $23.00 price target on the stock. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.00.

BridgeBio Oncology Therapeutics Stock Performance

The company has a market cap of $713.07 million, a PE ratio of -5.86 and a beta of 0.51. The stock's 50-day moving average is $10.34.

Institutional Trading of BridgeBio Oncology Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd increased its position in BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company's stock valued at $358,000 after purchasing an additional 5,249 shares during the period. Quadrature Capital Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter worth about $162,000. Catalio Capital Management LP bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $5,142,000. Armistice Capital LLC boosted its stake in shares of BridgeBio Oncology Therapeutics by 142.7% during the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company's stock valued at $12,520,000 after purchasing an additional 588,000 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP grew its holdings in shares of BridgeBio Oncology Therapeutics by 21.2% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company's stock worth $28,317,000 after acquiring an additional 395,608 shares during the period. Institutional investors own 54.89% of the company's stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics NASDAQ: BBOT is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.